EADV 2025｜银屑病研究新进展：发病机制、共病及药物

在本届EADV巴黎大会上，波尔图大学皮肤科教授Tiago Torres博士为我们带来了银屑病治疗领域的最新进展。

Torres教授在专题会议中深入探讨了银屑病的发病机制，重点解析了IL-23和IL-17的核心作用，同时也涵盖了I型干扰素、TNF-α和IL-22等其他关键细胞因子。讨论还延伸至银屑病的重要共病，如抑郁症和心脏代谢疾病，并回顾了当前能够使绝大多数患者实现皮损清除或几乎清除的强大治疗武器库。

此外，Torres教授重点介绍了几项令人振奋的治疗新突破：包括在研TYK2抑制剂Zasocitinib、可靶向所有IL-23受体的新型口服肽类药物Icotrokinra（其在疗效上显示出优于另一款TYK2抑制剂氘可来昔替尼的潜力），以及靶向IL-23的长效抗体ORKA-001的初步数据。

本次大会充分展示了银屑病管理正朝着更精准、更有效、更全面的方向飞速发展，未来可期。  

At this year's EADV congress in Paris, Professor Tiago Torres from the University of Porto shared exciting updates in the field of psoriasis treatment.

During a dedicated psoriasis session, Prof. Torres delved into the disease's pathogenesis, highlighting the pivotal roles of IL-23 and IL-17, while also acknowledging other crucial cytokines like Type I Interferons, TNF-alpha, and IL-22. The discussion extended to important comorbidities such as depression and cardiometabolic diseases, and reviewed the current powerful therapeutic arsenal that allows most patients to achieve clear or almost clear skin.

Furthermore, Prof. Torres spotlighted several promising therapeutic novelties. These included Zasocitinib, a TYK2 inhibitor currently in development; Icotrokinra, a novel oral peptide targeting all IL-23 receptors, which showed interesting efficacy and safety results with potential superiority over Deucravacitinib (another TYK2 inhibitor); and preliminary results for ORKA-001, an extended half-life antibody targeting IL-23.

The congress underscored the rapid evolution of psoriasis management towards more precise, effective, and comprehensive care, painting a bright future for patients.